Four Approved Frontline Treatments Benefit Patients with Chronic Myeloid Leukemia
Michael J. Mauro, MD, discusses how 4 FDA-approved frontline therapies are providing benefit to patients with chronic myeloid leukemia
Michael J. Mauro, MD, a hematologist at Memorial Sloan Kettering Cancer Center, discusses how 4 FDA-approved frontline therapies are providing benefit to patients with chronic myeloid leukemia (CML).
The first agent approved in the frontline setting of CML was imatinib (Gleevec), a tyrosine kinase inhibitor (TKI). Mauro says this agent has been safe and effective in newly diagnosed patients with CML, but now physicians should balance the merits of the other 3 approved agents.
Over the last few years, 3 second-generation TKIs have been approved in this setting as well, including nilotinib (Tasigna), dasantinib (Sprycel), and ponatinib (Iclusig). Physicians must balance the merits of this new class of agents, which have been reported with relative benefit and low toxicities, Mauro notes. In order to decide the best treatment, physicians should look at each individual patient and their goals in terms of treatment to figure out how to best use these therapies and manage the unique adverse events of each agent.
FDA Greenlights Treosulfan/Fludarabine Combo for AlloHSCT in AML and MDS
January 24th 2025The combination of treosulfan and fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia or myelodysplastic syndromes has been approved by the FDA.
Read More
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
What Is Dark Zone Lymphoma, and Is It Clinically Relevant?
January 16th 2025Dark zone lymphoma includes aggressive B-cell lymphomas with shared molecular features. While some respond to escalated treatment, others remain resistant, highlighting the need for targeted approaches to improve outcomes.
Read More
